Andrew Wilkes
Nurse Practitioner · Leominster, MANPI 1134883903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 495 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 32.5% of the total. 2025 is the largest year on record at $4,058, more than ten times the $213 reported in 2021. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 495 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Boehringer Ingelheim$818
- Regeneron Healthcare Solutions, Inc.$790
- Takeda Pharmaceuticals U.S.A., Inc.$394
- Sanofi$363
- plus $3K from 26 others
What the payments were for
- Food & beverage$10,99499%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 124 | $3,605 |
| GSK | 134 | $2,401 |
| Boehringer Ingelheim | 34 | $818 |
| Regeneron Healthcare Solutions, Inc. | 42 | $790 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $394 |
| Sanofi | 20 | $363 |
| Amgen | 14 | $281 |
| Actelion Pharmaceuticals US, Inc. | 9 | $262 |
| Mallinckrodt Hospital Products Inc. | 7 | $243 |
| United Therapeutics Corporation | 11 | $230 |
| Harmony Biosciences LLC | 8 | $200 |
| Axsome Therapeutics, Inc. | 7 | $167 |
| Inogen, Inc. | 11 | $130 |
| Electromed, Inc. | 6 | $109 |
| Viatris Specialty LLC | 6 | $105 |
| Mylan Specialty L.p. | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $102 |
| Verona Pharma, Inc. | 4 | $92 |
| Inspire Medical Systems, Inc. | 3 | $90 |
| Baxter Healthcare | 3 | $81 |
| Novartis | 4 | $74 |
| AbbVie | 3 | $72 |
| Jazz Pharmaceuticals Inc. | 2 | $70 |
| CMP Pharma, Inc. | 3 | $69 |
| Insmed, Inc. | 3 | $68 |
| Advanced Respiratory, Inc | 1 | $43 |
| Pfizer | 2 | $32 |
| Philips North America LLC | 1 | $28 |
| Lilly USA, LLC | 1 | $27 |
| Eisai Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Resmed Corp | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,107 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 890 | $691,473 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 354 | $251,853 |
| Breo ElliptaFluticasone/Vilanterol | 248 | $116,128 |
| Spiriva RespimatTiotropium Bromide | 172 | $113,621 |
| NucalaMepolizumab | 15 | $52,926 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $47,765 |
| Incruse ElliptaUmeclidinium Bromide | 93 | $38,963 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,055 | $32,496 |
| SymbicortBudesonide/Formoterol Fumarate | 117 | $31,241 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 128 | $31,158 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $19,236 |
| Ventolin HfaAlbuterol Sulfate | 209 | $13,722 |
| Wixela InhubFluticasone Propion/Salmeterol | 91 | $13,525 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $12,224 |
| Arnuity ElliptaFluticasone Furoate | 43 | $11,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $2,401 | $958,5921,361 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,605 | $295,318486 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $818 | $140,466221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Leominster
- Kaitlin ZuberLeominster$11K
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.